Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astri Therapeutics Inc (ATXS)

Astri Therapeutics Inc (ATXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 671,586
  • Shares Outstanding, K 54,913
  • Annual Sales, $ 0 K
  • Annual Income, $ -72,890 K
  • 60-Month Beta 0.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.62
Trade ATXS with:

Options Overview Details

View History
  • Implied Volatility 61.11% ( -16.36%)
  • Historical Volatility 61.93%
  • IV Percentile 17%
  • IV Rank 16.55%
  • IV High 261.03% on 03/08/24
  • IV Low 21.45% on 07/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 2.71
  • Today's Open Interest 1,272
  • Open Int (30-Day) 992

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate -0.35
  • Low Estimate -0.47
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +31.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.21 +32.79%
on 08/05/24
12.63 -3.17%
on 08/26/24
+0.80 (+7.00%)
since 07/30/24
3-Month
8.62 +41.88%
on 06/10/24
12.70 -3.70%
on 07/29/24
+3.22 (+35.74%)
since 05/30/24
52-Week
4.26 +187.09%
on 11/17/23
16.90 -27.63%
on 03/25/24
+3.43 (+38.98%)
since 08/29/23

Most Recent Stories

More News
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics Names Andrea Matthews Chief Business Officer

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological...

ATXS : 12.23 (+1.75%)
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic...

ATXS : 12.23 (+1.75%)

Business Summary

Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics,...

See More

Key Turning Points

3rd Resistance Point 13.33
2nd Resistance Point 12.95
1st Resistance Point 12.59
Last Price 12.23
1st Support Level 11.85
2nd Support Level 11.47
3rd Support Level 11.11

See More

52-Week High 16.90
Last Price 12.23
Fibonacci 61.8% 12.07
Fibonacci 50% 10.58
Fibonacci 38.2% 9.09
52-Week Low 4.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar